Uveitic Macular Edema

All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.

Article initiated by:

Jason Zheng, Jainam Shah, Sachin Pathuri, Bruce Becker, MD, Andrew Go Lee, MD

All contributors:

Jason Zheng, Jainam Shah, Sachin Pathuri, Andrew Go Lee, MD, Bruce Becker, MD

Assigned editor:

Review:

Assigned status Update Pending

.

add
Contributing Editors:	add

Uveitic macular edema is a serious sight-threatening complication of uveitis and a major cause of visual impairment due to inflammatory disruption of the blood–retinal barrier and subsequent fluid accumulation within the macula. Diagnosis relies on multimodal imaging, particularly optical coherence tomography, to identify characteristic structural changes and guide management. Treatment focuses on controlling underlying inflammation with corticosteroids and immunomodulatory or biologic therapies, with prognosis generally favorable when inflammation is promptly managed, although relapses are common.

Background

Uveitic macular edema (UME) refers to the accumulation of extracellular fluid within the macula secondary to intraocular inflammation. Fluid may localize within the retinal layers as cystoid spaces, present as diffuse retinal thickening, or collect in the subretinal space between the neurosensory retina and the retinal pigment epithelium. UME can occur in association with any form of uveitis and represents the most common sight-threatening complication of uveitic disease as well as a leading cause of visual impairment among affected patients.

Anatomical Subtypes of Uveitis

Because the risk, clinical behavior, and prognosis of UME vary according to the site of inflammation, uveitis is anatomically classified into four major categories:

• Anterior uveitis involves the iris and ciliary body and is confined primarily to the anterior segment.
• Intermediate uveitis predominantly affects the vitreous, with inflammation centered near the pars plana.
• Posterior uveitis involves the retina, choroid, and posterior vitreous.
• Panuveitis denotes inflammation affecting both anterior and posterior segments simultaneously.

This classification is clinically important because macular edema occurs more frequently and tends to be more persistent in intermediate, posterior, and panuveitis compared with isolated anterior uveitis.

Epidemiology

UME is a common complication of intraocular inflammation and represents the leading cause of visual impairment among patients with uveitis. UME is responsible for nearly 40% of visual impairment in uveitis patients, underscoring its major contribution to long-term visual morbidity. In non-infectious uveitis (NIU), the reported prevalence of UME ranges from approximately 8% to 13%, although estimates vary depending on disease subtype, duration of inflammation, and methods of detection.

The epidemiology of macular edema in infectious uveitis is less well defined. Infectious etiologies account for approximately 10% to 20% of uveitis cases in developed countries and up to 30% to 50% in developing regions, suggesting that the global burden of UME may be higher in areas where infectious uveitis predominates.

Certain clinical features are associated with an increased likelihood of developing UME, particularly those reflecting greater inflammatory burden or posterior segment involvement as described in the table below.

Clinical Factor	Proposed Explanation
Intermediate uveitis	Persistent vitreous inflammation exposes the macula to inflammatory mediators
Posterior uveitis	Direct retinal and choroidal involvement disrupts the blood–retinal barrier
Panuveitis	Diffuse inflammation increases cumulative vascular permeability
Bilateral disease	Suggests systemic immune activation and chronicity
Associated systemic inflammatory disease	Heightened cytokine-driven vascular leakage

Pathophysiology

UME results from inflammatory disruption of the blood–retinal barrier (BRB), which normally maintains retinal fluid homeostasis. The inner BRB is formed by nonfenestrated retinal capillary endothelial cells joined by tight junctions (zonula occludens), while the outer BRB consists of tight junctions between retinal pigment epithelium (RPE) cells that prevent fluid movement from the choroid into the neurosensory retina. In uveitis, breakdown of these barriers during intraocular inflammation permits vascular leakage and accumulation of extracellular fluid within the macula.

Inflammatory mediators released during uveitis alter endothelial permeability and damage junctional integrity. Key cytokines implicated include:

• Tumor necrosis factor–alpha (TNF-α)
• Interferon–gamma (IFN-γ)
• Interleukin-2 (IL-2)
• Interleukin-17 (IL-17)
• Interleukin-6 (IL-6)

IL-6 plays a particularly important role by inducing vascular endothelial growth factor (VEGF) production and downregulating tight junction proteins in retinal endothelial cells, thereby promoting vascular leakage.

Role of Müller Cell Dysfunction

Müller cells are the principal retinal glial cells spanning the full thickness of the retina and are essential for regulating retinal hydration. Under physiologic conditions, these cells transport excess potassium and water from the retinal interstitium into blood vessels and the vitreous through:

• Inward rectifying potassium channel 4.1 (Kir4.1)
• Aquaporin-4 (AQP4)

During uveitis, elevated cytokines and VEGF disrupt this regulatory system:

• Downregulation of Kir4.1 and AQP4 impairs potassium and water transport, preventing clearance of interstitial fluid and leading to accumulation within the inner retinal layers.
• Activated Müller cells release additional cytokines and VEGF, creating a self-perpetuating cycle of inflammation, vascular permeability, and edema formation.

This combination of vascular barrier breakdown and impaired glial fluid regulation explains why UME can persist even after overt inflammatory signs begin to improve.

Clinical Presentation

UME may be asymptomatic in its early stages and is frequently detected on imaging before patients recognize visual changes. As edema progresses and involves the fovea, patients typically develop symptoms related to impaired central macular function. Common presenting features include:

• Blurred or decreased central vision, the hallmark symptom of UME.
  • Patients with UME demonstrate significantly worse visual acuity compared with those who have uveitis without macular edema.
• Difficulty reading or performing near tasks, reflecting reduced foveal resolution.
• Metamorphopsia, or distortion of straight lines, caused by disruption of normal retinal architecture.
• Micropsia, in which objects appear smaller due to altered photoreceptor alignment.

Because symptoms may be subtle early in the disease course, OCT screening is often necessary in patients with active or chronic uveitis to detect macular involvement before permanent structural damage occurs.

Imaging and Diagnosis

Diagnosis of uveitic macular edema is established using multimodal imaging, primarily optical coherence tomography (OCT) and fundus fluorescein angiography (FFA). These modalities provide complementary structural and functional information.

Optical Coherence Tomography

OCT is the most sensitive tool for detecting and monitoring UME and allows detailed visualization of retinal morphology. It identifies several characteristic patterns, which may occur individually or in combination (Figure 1):

• Cystoid macular edema (CME): Discrete hyporeflective intraretinal cystic spaces separated by thin hyperreflective septa.
• Diffuse macular edema (DME): Increased macular thickness with small hyporeflective areas creating a spongiform appearance of the retina.
• Serous retinal detachment (SRD): Separation of the neurosensory retina from the retinal pigment epithelium due to subretinal fluid accumulation.

These morphologic patterns are not mutually exclusive and frequently coexist within the same eye.

Fundus Fluorescein Angiography

FFA evaluates retinal vascular permeability and helps confirm inflammatory leakage patterns associated with UME.

• CME: Demonstrates a characteristic petaloid or stellate pattern of perifoveal leakage caused by dye pooling in cystoid spaces.

• DME: Shows diffuse, poorly demarcated leakage without a petaloid configuration.

Although FFA is valuable for assessing vascular leakage, OCT is more sensitive for detecting SRD. One study found that FFA failed to identify subretinal fluid in approximately 54.55% of cases that were visible on OCT.

Treatment

Treatment of UME is directed at controlling the underlying intraocular inflammation while reducing macular fluid and preserving visual function. Because UME is primarily an inflammatory process, anti-inflammatory therapy remains the cornerstone of management, with adjunctive agents used in selected cases. A detailed discussion of clinical trials, injection strategies, and comparative therapeutic outcomes is available in the Uveitic Macular Edema section within the Treatment of Uveitis Eyewiki article.

Corticosteroids

Corticosteroids are considered first-line therapy for most cases of UME due to their rapid suppression of inflammatory cytokines and restoration of blood–retinal barrier integrity. They may be administered through multiple routes depending on disease severity, laterality, and systemic considerations, including:

• Topical corticosteroids (limited role, mainly in anterior uveitis)
• Periocular corticosteroid injections
• Intravitreal corticosteroid injections or implants
• Systemic corticosteroids for bilateral or severe disease

Further discussion of corticosteroid delivery approaches is available in the Uveitic Macular Edema section within the Treatment of Uveitis Eyewiki article.

Steroid-Sparing Immunomodulatory Therapy

For patients with chronic, recurrent, or steroid-dependent disease, systemic immunomodulatory therapy (IMT) is often required to achieve sustained control of inflammation and prevent repeated episodes of macular edema. These agents target T-cell activation and other immune pathways involved in uveitic disease.

Detailed indications and agent selection are reviewed in Immunomodulatory Therapy for Uveitis.

Biologic Therapy: IL-6 Inhibition (Tocilizumab)

Interleukin-6 has been identified as a key mediator in the pathogenesis of UME through its effects on vascular permeability and VEGF upregulation. Tocilizumab, an IL-6 receptor antagonist, has demonstrated efficacy in refractory UME, particularly in cases resistant to corticosteroids and conventional IMT.

Additional information is available in the Tocilizumab Eyewiki article.

Anti-VEGF Therapy

Anti-VEGF agents may be used as adjunctive therapy in selected patients, particularly when vascular permeability contributes significantly to edema or when there is incomplete response to anti-inflammatory treatment. Unlike diabetic macular edema, anti-VEGF therapy in UME does not address the primary inflammatory driver and is therefore typically not used as monotherapy. Additional information regarding anti-VEGF therapy is available in the Uveitic Macular Edema section within the Treatment of Uveitis Eyewiki article.

Prognosis

Visual impairment caused by UME is frequently reversible with appropriate control of inflammation. Long-term follow-up data suggest that meaningful anatomic and functional recovery is achievable in many patients:

The Seven-Year Outcomes of Uveitic Macular Edema analysis from the Multicenter Uveitis Steroid Treatment (MUST) randomized clinical trial evaluated long-term outcomes in eyes with UME and found that approximately 94% of affected eyes demonstrated cumulative resolution over seven years. Eyes in which macular edema resolved experienced a mean visual improvement of about 6 letters compared with periods when edema was present, supporting the potential for functional recovery with adequate treatment.

Despite these favorable outcomes, relapse is common and reflects the chronic, recurrent nature of uveitic disease. In the same cohort, a cumulative relapse rate of 43% was observed within seven years among eyes that initially achieved resolution. These findings highlight the importance of sustained inflammatory control and long-term monitoring.

Prognosis varies by anatomic subtype of uveitis. Eyes with isolated anterior uveitis generally experience more favorable visual outcomes than those with intermediate, posterior, or panuveitis. One study demonstrated that anterior uveitis was associated with a greater likelihood of achieving and maintaining an approximately two-line improvement in visual acuity within one year compared with intermediate, posterior, or panuveitis. Similarly, other investigations have shown that eyes with anterior segment–predominant inflammation more frequently achieve clinically meaningful visual gains than those with posterior involvement. The presence of anterior chamber inflammatory cells has also been associated with more favorable outcomes, likely reflecting active, treatment-responsive inflammation rather than chronic structural damage to the macula.